Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00680589
Recruitment Status : Completed
First Posted : May 20, 2008
Last Update Posted : March 28, 2011
Information provided by:
Memorial Sloan Kettering Cancer Center

Brief Summary:

The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body. TYRP2 is a substance found in melanoma cells that helps to produce their black color. The DNA used in this study is the gene for mouse TYRP2.

The gene is introduced into bacteria, which are grown in large quantities. The DNA vaccine is then made from bacteria that is inactive.

We would like to see if we can immunize patients against TYRP2 by injecting mouse TYRP2 DNA. We will also follow the patients closely to see if there are any side effects. Mouse TYRP2 DNA is very similar to human TYRP2 DNA. We believe, based on lab experiments, that injection of mouse TYRP2 DNA could result in the production of immune substances (antibodies and T cells) that recognize melanoma cells. Antibodies are substances produced by your immune system to defend your body against bacteria and viruses. T cells are a type of white blood cell that can also fight infections. The small differences between mouse and human TYRP2 may allow your immune system to make the antibodies and T cells against melanoma. There is no evidence yet that injection of TYRP2 DNA results in any clinical benefit in patients.

Condition or disease Intervention/treatment Phase
Melanoma Biological: injection of mouse TYRP2 DNA Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Injection of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response
Study Start Date : July 2006
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: 1
Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
Biological: injection of mouse TYRP2 DNA
Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.

Primary Outcome Measures :
  1. To evaluate the safety and feasibility of intra-muscular DNA injection with mouse TYRP2 DNA. Doses will be escalated by groups to determine the maximal tolerated dose. [ Time Frame: conclusion of study ]

Secondary Outcome Measures :
  1. A secondary endpoint is to observe the patients for evidence of any antitumor response generated after immunizations. [ Time Frame: conclusion of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   7 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • For all patients, pathology slides must be reviewed by the Memorial Hospital Department of Pathology for confirmation of melanoma diagnosis.
  • Patients must be HLA-A*0201 positive.
  • Patients must have a Karnofsky performance status of at least 80.
  • Patients must be free of detectable brain metastases.
  • Patients must have adequate organ and marrow function as defined below:
  • WBC ≥ than or = to 3,000/μL
  • Absolute neutrophil count ≥ than or = to 1,500/μL
  • Platelets ≥ than or = to 100,000/μL
  • Total bilirubin ≤ than or = to 1.5X upper normal institutional limits
  • LDH ≤ than or = to 2 X institutional upper limit of normal
  • Albumin ≥ than or = to 3.5 mg/dl
  • Creatinine ≤ than or = to 2.0 mg/dl
  • Hemoglobin ≥ than or = to 10 Gm/dl
  • Liver AST, ALT ≤ than or = to 2.5 x ULN
  • Patients must have no known HIV positivity
  • Pediatric patients are eligible if weight is > 25 kg and parent/guardian completes informed assent process.
  • Patients must understand and sign an informed consent and have specifically declined all standard or approved therapies for which they would be considered eligible. Parent or legal guardians of patients who are minors will sign the informed consent form.
  • As part of the consent process, patients must agree to use contraception while on study.

Exclusion Criteria:

  • Patients who have had chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. For nitrosoureas, at last six weeks must have elapsed.
  • Patients with Grade I fever, active infection, or antibiotics within 72 hours prior to study.
  • Patients who have previously been immunized with any class of vaccine containing TYRP2, including whole cell, shed antigen or cell lysate vaccine.
  • Patients with a history of collagen vascular, rheumatological, or other autoimmune disorders.
  • Any medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to respond immunologically to vaccines is grounds for exclusion, at the discretion of the Principal Investigator or co-Principal Investigators.
  • Patients who have preexisting retinal or choroidal eye disease.
  • Patients with serious underlying medical conditions that could be exacerbated by participation, active infections requiring antimicrobial drugs or active bleeding.
  • Pregnant women or women who are nursing are not eligible. Women of child-bearing potential and sexually active men must be using appropriate contraception during the course of this study. Women of child-bearing potential must not be pregnant (negative βHCG within 2 weeks of immunization) nor be nursing during treatment.
  • Patients receiving other investigational agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00680589

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Principal Investigator: Jedd Wolchok, MD Memorial Sloan Kettering Cancer Center

Additional Information:
Responsible Party: Jedd Wolchok, MD, Memorial Sloan-Kettering Cancer Center Identifier: NCT00680589     History of Changes
Other Study ID Numbers: 06-052
First Posted: May 20, 2008    Key Record Dates
Last Update Posted: March 28, 2011
Last Verified: March 2011

Keywords provided by Memorial Sloan Kettering Cancer Center:
TYRP2 DNA Vaccine

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas